Oxford Immunotec Global (OXFD) Stock Rating Lowered by BidaskClub

Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Thursday.

A number of other equities analysts have also weighed in on OXFD. BTIG Research initiated coverage on Oxford Immunotec Global in a research note on Thursday, September 28th. They set a “buy” rating and a $21.00 price objective on the stock. Cowen reissued a “buy” rating and set a $19.00 price objective on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. Zacks Investment Research raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Piper Jaffray Companies lowered their price objective on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 31st. Finally, ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $19.75.

Shares of Oxford Immunotec Global (NASDAQ:OXFD) opened at $11.51 on Thursday. The company has a market capitalization of $292.21, a P/E ratio of -5.73 and a beta of -0.09. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global has a 12-month low of $10.81 and a 12-month high of $19.51.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now owns 17,778 shares of the company’s stock, valued at $237,336.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.11% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC lifted its stake in shares of Oxford Immunotec Global by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after purchasing an additional 1,845 shares during the last quarter. Alliancebernstein L.P. acquired a new position in shares of Oxford Immunotec Global in the 2nd quarter valued at $247,000. Asymmetry Capital Management L.P. acquired a new position in shares of Oxford Immunotec Global in the 2nd quarter valued at $273,000. The Manufacturers Life Insurance Company lifted its stake in shares of Oxford Immunotec Global by 8.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Oxford Immunotec Global by 9.1% in the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after purchasing an additional 2,053 shares during the last quarter. 89.35% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/oxford-immunotec-global-oxfd-stock-rating-lowered-by-bidaskclub.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply